MicroRNA-196a and -196b as potential biomarkers for the early detection of familial pancreatic cancer

Translational Oncology

Volumn 7, Issue 4, 2014, Pages 464-471

  Slater, Emily P ^a   Strauch, Konstantin ^b,c   Rospleszcz, Susanne ^b,c   Ramaswamy, Annette ^a   Esposito, Irene ^d   Klöppel, Günter ^d   Matthäi, Elvira ^a   Heeger, Kristin ^a   Fendrich, Volker ^a   Langer, Peter ^a   Bartsch, Detlef K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MICRORNA; MICRORNA 155; MICRORNA 196A; MICRORNA 196B; MICRORNA 21; MICRORNA 210; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC PANCREATITIS; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; GENOTYPING TECHNIQUE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SENSITIVITY AND SPECIFICITY;

EID: 84907332014     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.05.007     Document Type: Article

References (45)

1. Bartsch DK, Kress R, Sina-Frey M, Grützmann R, Gerdes B, Pilarsky C, Heise JW, Schulte KM, Colombo-Benkmann M, and Schleicher C, et al (2004). Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110, 902-906.
2. Hemminki K and Li X (2003). Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 103, 525-530.
3. Brand RE, Lerch MM, Rubinstein WS, Neoptolemos JP, Whitcomb DC, Hruban RH, Brentnall TA, Lynch HT, and Canto MI (2007). Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56, 1460-1469.
4. Bartsch DK, Gress TM, and Langer P (2012). Familial pancreatic cancer- current knowledge. Nat Rev Gastroenterol Hepatol 9, 445-453.
5. Hahn SA, Greenhalf W, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, and Raeburn JA, et al (2003). BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95, 214-221.
6. Slater EP, Langer P, Fendrich V, Habbe N, Chaloupka B, Matthäi E, Sina M, Hahn SA, and Bartsch DK (2010). Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer 9, 335-343.
7. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, Greenhalf W, and Bartsch DK (2010). PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78, 490-494.
8. Bartsch DK, Sina-Frey M, Lang S, Wild A, Gerdes B, Barth P, Kress R, Grützmann R, Colombo-Benkmann M, and Ziegler A, et al (2002). CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236, 730-737.
9. Roberts NJ, Jiao Y, Yu J, Kopelovich L, Petersen GM, Bondy ML, Gallinger S, Schwartz AG, Syngal S, and Cote ML, et al (2012). ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2, 41-46.
10. Sipos B, Frank S, Gress T, Hahn S, and Klöppel G (2009). Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 9, 45-54.
11. Shi C, Klein AP, Goggins M, Maitra A, Canto M, Ali S, Schulick R, Palmisano E, and Hruban RH (2009). Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 15, 7737-7743.
12. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, and Rothmund M, et al (2009). 5 Years of prospective screening of high risk individuals from familial pancreatic cancer- families. Gut 58, 1410-1418.
13. Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P, Bartsch DK, Langer P, Chiblak S, and Dürr A, et al (2012). Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 226, 723-734.
14. Bartsch DK, Dietzel K, Bargello M, Matthaei E, Kloeppel G, Esposito I, Heverhagen JT, Gress TM, Slater EP, and Langer P (2013). Multiple small imaging branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer 12, 89-96.
15. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, and DePinho RA (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20, 1218-1249.
16. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, and Hitt BA, et al (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450.
17. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, and Tuveson DA (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483.
18. Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, Slater EP, Maitra A, and Bartsch DK (2010). The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59, 630-637.
19. Esquela-Kerscher A and Slack FJ (2006). Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6, 259-269.
20. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, and Melamed N, et al (2008). Serum microRNAs Are promising novel biomarkers. PLoS One 3, e3148.
21. Song M-Y, Pan K-F, Su H-J, Zhang L, Ma J-L, Li J-Y, Yuasa Y, Kang D, Kim YS, and You W-C (2012). Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 7, e33608.
22. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM, and Sen S (2009). MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2, 807-813.
23. Hanahan D (1985). Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-122.
24. Sobin LH, Gospodarowicz MK, and Wittekind CH (2009). UICC: TNM classification of malignant tumours. 7th edn.Oxford, England: Wiley-Blackwell; 2009.
25. Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ, Gutmann EJ, Suriawinata AA, and Marc Pipas J, et al (2008). Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 54, 1716-1724.
26. Munding JB, Adai AT, Maghnouj A, Urbanik A, Zöllner H, Liffers ST, Chromik AM, Uhl W, Szafranska-Schwarzbach AE, and Tannapfel A, et al (2012). Global microRNA expression profiling of microdissected tissues identifies miR- 135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 131, E86-95.
27. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, and Croce CM (2007). MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901-1908.
28. Habbe N, Koorstra J, Mendell J, Offerhaus G, Ryu J, Feldmann G, Mullendore M, Goggins M, Hong S, and Maitra A (2009). MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 8, 340-346.
29. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, and Maitra A (2010). Aberrant microRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 10, 66-73.
30. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E, andHahn SA (2007).MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26, 4442-4452.
31. Seux M, Iovanna J, Dagorn JC, and Dusetti NJ (2009). MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues. Pancreatology 9, 66-72.
32. Zhang Y, Li M, Wang H, Fisher W, Lin P, Yao Q, and Chen C (2009). Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by realtime PCR analysis. World J Surg 33, 698-709.
33. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, and Koong AC (2010). Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 3, 109-113.
34. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, and Petersen G, et al (2012). Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 142, 796-804.
35. Yu J, Li A, Hong S-M, Hruban RH, and Goggins M (2012). MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 18, 981-992.
36. Wan C, Shen Y, Yang T, Wang T, Chen L, and Wen F (2012). Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. Arch Med Sci 8, 749-755.
37. Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, Wang X, Gong Y, Wang W, and Kong X (2012). Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131, 683-691.
38. Bauer AS, Keller A, Costello E, Greenhalf W, Bier M, Borries A, Beier M, Neoptolemos J, Büchler M, and Werner J, et al (2012). Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One 7, e34151.
39. du RieuMC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrère N, and Buscail L, et al (2010). MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 56, 603-612.
40. LaConti JJ, Shivapurkar N, Preet A, DeslattesMays A, Peran I, Kim SE, Marshall JL, Riegel AT, and Wellstein A (2011). Tissue and serum microRNAs in the KrasG12D transgenic animal model and in patients with pancreatic cancer. PLoS One 6, e20687.
41. Costello E, Greenhalf W, and Neoptolemos JP (2012). New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9, 435-444.
42. Baraniskin A, Nöpel-Dünnebacke S, Ahrens M, Jensen SG, Zöllner H, Maghnouj A, Wos A, Mayerle J, Munding J, and Kost D, et al (2013). Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer 132, E48-57.
43. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, and Hirajima S, et al (2013). Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 108, 361-369.
44. Wang WS, Liu LX, Li GP, Chen Y, Li CY, Jin DY, and Wang XL (2013). Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Cancer Prev Res (Phila) 6, 331-338.
45. Xue Y, AbouTayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth Jr RJ, Suriawinata AA, and Tsongalis GJ (2013). MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm. Cancer Genet 206, 217-221.